Edwards Lifesciences Other countries — Operating Loss Carryforwards, Valuation Allowance increased by 18.0% to $74.60M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 18.0%, from $63.20M to $74.60M. This increase may warrant attention — for this metric, lower values are generally preferred.
A decrease in the allowance is a positive signal indicating improved profitability expectations in those international markets.
The valuation allowance established against deferred tax assets related to operating loss carryforwards in international...
Standard valuation allowance disclosure required under ASC 740 for multinational entities.
ew_segment_other_countries_operating_loss_carryforwards_valuation_allowance| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $50.80M | $50.60M | $54.50M | $63.20M | $74.60M |
| QoQ Change | — | -0.4% | +7.7% | +16.0% | +18.0% |
| YoY Change | — | -0.4% | +7.7% | +16.0% | +18.0% |